1. A living WHO guideline on drugs for covid-19
2. NHS England . Interim clinical commissioning policy: Antivirals or neutralising monoclonal antibodies for non-hospitalised patients with COVID-19 (version 6). NHS, 2022. www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2021/12/C1650-interim-ccp-antivirals-or-neutralising-monoclonal-antibodies-non-hospitalised-patients-with-covid19-v6.pdf
3. NHS England . Interim clinical commissioning policy: Baricitinib for patients hospitalised due to COVID-19 (adults and children aged 2 years and over). NHS, 2022. www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2022/05/C1643-i-interim-clin-comm-pol-baricitinib-for-patients-hospitalised-adults-and-children-aged-2-and-over.pdf
4. Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
5. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial;Spinner;JAMA,2020